Coeptis Therapeutics Inc Cash Flow Conversion Efficiency
Coeptis Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Coeptis Therapeutics Inc (COEP) has a cash flow conversion efficiency ratio of -0.165x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.15 Million) by net assets ($13.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Coeptis Therapeutics Inc (2004–2024)
Cash flow conversion efficiency of Coeptis Therapeutics Inc from 2004 to 2024. This chart illustrates how Coeptis Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Coeptis Therapeutics Inc (COEP) share price today for real-time trading data and today's change.
Coeptis Therapeutics Inc Cash Flow Conversion Ratio Explained
Coeptis Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Coeptis Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coeptis Therapeutics Inc ranked by their cash flow conversion efficiency. Also see COEP stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cps Technologies
NASDAQ:CPSH
|
-66.268x |
|
GOLDGROUP MINING INC.
F:55G0
|
-0.776x |
|
Media Prima Bhd
KLSE:4502
|
0.072x |
|
Flag Ship Acquisition Corp. Unit
NASDAQ:FSHPU
|
-0.006x |
|
Engenco Ltd
AU:EGN
|
0.101x |
|
Magna Prima Bhd
KLSE:7617
|
0.138x |
|
L.P.N. Development Public Company Limited
BK:LPN
|
0.018x |
|
Case Group AB
ST:CASE
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Coeptis Therapeutics Inc (2004–2024)
The table below shows the annual cash flow conversion efficiency of Coeptis Therapeutics Inc from 2004 to 2024. Review free cash flow generation of Coeptis Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.87 Million | $-6.65 Million | -1.719x | -97.56% |
| 2023-12-31 | $4.45 Million | $-3.88 Million | -0.870x | -7.86% |
| 2022-12-31 | $4.80 Million | $-3.88 Million | -0.807x | +57.75% |
| 2021-12-31 | $2.35 Million | $-4.49 Million | -1.910x | -413.23% |
| 2020-12-31 | $-5.14 Million | $-3.14 Million | 0.610x | +110.62% |
| 2019-12-31 | $15.69K | $-90.07K | -5.739x | +87.74% |
| 2018-12-31 | $17.93K | $-839.06K | -46.804x | -6291.45% |
| 2005-12-31 | $-551.66K | $-417.02K | 0.756x | +112.84% |
| 2004-12-31 | $-264.01K | $1.55 Million | -5.885x | -- |
About Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more